结合多表位 MoonTags 和标记纳米抗体,在体内细胞特异性 PET 成像中放大信号。

IF 3.6 4区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Nuclear medicine and biology Pub Date : 2024-06-20 DOI:10.1016/j.nucmedbio.2024.108937
Katharina S. Höffgen , Jennifer Dabel , Christian P. Konken , Dominic A. Depke , Sven Hermann , Wolfgang Dörner , Sonja Schelhaas , Michael Schäfers , Henning D. Mootz
{"title":"结合多表位 MoonTags 和标记纳米抗体,在体内细胞特异性 PET 成像中放大信号。","authors":"Katharina S. Höffgen ,&nbsp;Jennifer Dabel ,&nbsp;Christian P. Konken ,&nbsp;Dominic A. Depke ,&nbsp;Sven Hermann ,&nbsp;Wolfgang Dörner ,&nbsp;Sonja Schelhaas ,&nbsp;Michael Schäfers ,&nbsp;Henning D. Mootz","doi":"10.1016/j.nucmedbio.2024.108937","DOIUrl":null,"url":null,"abstract":"<div><p>Immunorecognition provides an excellent basis for targeted imaging techniques covering a wide range from basic research to diagnostics and from single cells to whole organisms. Fluorescence- or radioisotope-labeled antibodies, antibody fragments or nanobodies enable a direct signal readout upon binding and allow for versatile imaging from microscopy to whole-body imaging. However, as the signal intensity directly correlates with the number of labeled antibodies bound to their epitopes (1:1 binding), sensitivity for low-expressing epitopes can be limiting for visualization. For the first time, we developed poly-epitope tags with multiple copies (1 to 7) of a short peptide epitope, specifically the MoonTag, that are recognized by a labeled nanobody and aimed at signal amplification in microscopy and cell-specific PET imaging. In transiently transfected HeLa cells or stably transduced A4573 cells we characterized complex formation and <em>in vitro</em> signal amplification. Indeed, using fluorescently and radioactively labeled nanobodies we found an approximately linear signal amplification with increasing numbers of epitope copies <em>in vitro</em>. To test the poly-epitope approach <em>in vivo</em>, A4573 tumor cells were injected subcutaneously into the shoulder of NSG mice, with A4573 tumor cells expressing a poly-epitope of 7 MoonTags on one side and WT cells on the other side. Using a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody, we performed PET/CT imaging at day 8–9 after tumor implantation. Specific binding of a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody was observed in 7xMoonTag tumors (1.7 ± 0.5%ID/mL) by PET imaging, showing significantly higher radiotracer accumulation compared to the WT tumors (1.1 ± 0.3%ID/mL; <em>p</em> &lt; 0.01). <em>Ex vivo</em> gamma counter measurements confirmed significantly higher uptake in 7xMoonTag tumors compared to WT tumors (<em>p</em> &lt; 0.001). In addition, MoonTag nanobody binding was detected by autoradiography which was spatially matched with histological analysis of the tumor tissues. In conclusion, we expect nanobody-based poly-epitope tag strategies to be widely applicable for multimodal imaging techniques given the advantageous properties of nanobodies and their amenability to genetic and chemical engineering.</p></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"136 ","pages":"Article 108937"},"PeriodicalIF":3.6000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0969805124000635/pdfft?md5=538e2cf736ea2337611b25300b461524&pid=1-s2.0-S0969805124000635-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Combining poly-epitope MoonTags and labeled nanobodies for signal amplification in cell-specific PET imaging in vivo\",\"authors\":\"Katharina S. Höffgen ,&nbsp;Jennifer Dabel ,&nbsp;Christian P. Konken ,&nbsp;Dominic A. Depke ,&nbsp;Sven Hermann ,&nbsp;Wolfgang Dörner ,&nbsp;Sonja Schelhaas ,&nbsp;Michael Schäfers ,&nbsp;Henning D. Mootz\",\"doi\":\"10.1016/j.nucmedbio.2024.108937\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Immunorecognition provides an excellent basis for targeted imaging techniques covering a wide range from basic research to diagnostics and from single cells to whole organisms. Fluorescence- or radioisotope-labeled antibodies, antibody fragments or nanobodies enable a direct signal readout upon binding and allow for versatile imaging from microscopy to whole-body imaging. However, as the signal intensity directly correlates with the number of labeled antibodies bound to their epitopes (1:1 binding), sensitivity for low-expressing epitopes can be limiting for visualization. For the first time, we developed poly-epitope tags with multiple copies (1 to 7) of a short peptide epitope, specifically the MoonTag, that are recognized by a labeled nanobody and aimed at signal amplification in microscopy and cell-specific PET imaging. In transiently transfected HeLa cells or stably transduced A4573 cells we characterized complex formation and <em>in vitro</em> signal amplification. Indeed, using fluorescently and radioactively labeled nanobodies we found an approximately linear signal amplification with increasing numbers of epitope copies <em>in vitro</em>. To test the poly-epitope approach <em>in vivo</em>, A4573 tumor cells were injected subcutaneously into the shoulder of NSG mice, with A4573 tumor cells expressing a poly-epitope of 7 MoonTags on one side and WT cells on the other side. Using a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody, we performed PET/CT imaging at day 8–9 after tumor implantation. Specific binding of a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody was observed in 7xMoonTag tumors (1.7 ± 0.5%ID/mL) by PET imaging, showing significantly higher radiotracer accumulation compared to the WT tumors (1.1 ± 0.3%ID/mL; <em>p</em> &lt; 0.01). <em>Ex vivo</em> gamma counter measurements confirmed significantly higher uptake in 7xMoonTag tumors compared to WT tumors (<em>p</em> &lt; 0.001). In addition, MoonTag nanobody binding was detected by autoradiography which was spatially matched with histological analysis of the tumor tissues. In conclusion, we expect nanobody-based poly-epitope tag strategies to be widely applicable for multimodal imaging techniques given the advantageous properties of nanobodies and their amenability to genetic and chemical engineering.</p></div>\",\"PeriodicalId\":19363,\"journal\":{\"name\":\"Nuclear medicine and biology\",\"volume\":\"136 \",\"pages\":\"Article 108937\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0969805124000635/pdfft?md5=538e2cf736ea2337611b25300b461524&pid=1-s2.0-S0969805124000635-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear medicine and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0969805124000635\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805124000635","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

从基础研究到诊断,从单细胞到整个生物体,免疫认知为靶向成像技术奠定了坚实的基础。荧光或放射性同位素标记的抗体、抗体片段或纳米抗体可在结合后直接读出信号,实现从显微镜到全身成像的多功能成像。然而,由于信号强度与其表位结合的标记抗体数量直接相关(1:1 结合),低表达表位的灵敏度会限制可视化。我们首次开发了多表位标签,该标签具有多个短肽表位拷贝(1 至 7),特别是 MoonTag,可被标记的纳米抗体识别,旨在放大显微镜和细胞特异性 PET 成像中的信号。在瞬时转染的 HeLa 细胞或稳定转染的 A4573 细胞中,我们鉴定了复合物的形成和体外信号放大。事实上,使用荧光和放射性标记的纳米抗体,我们发现随着表位拷贝数的增加,体外信号放大近似线性。为了在体内测试多表位方法,我们将 A4573 肿瘤细胞皮下注射到 NSG 小鼠的肩部,一边是表达 7 个 MoonTags 的多表位 A4573 肿瘤细胞,另一边是 WT 细胞。我们使用[68Ga]标记的NODAGA结合MoonTag纳米抗体,在肿瘤植入后第8-9天进行了PET/CT成像。通过 PET 成像,我们在 7xMoonTag 肿瘤(1.7 ± 0.5%ID/mL)中观察到了[68Ga]标记的 NODAGA 连接的 MoonTag 纳米抗体的特异性结合,与 WT 肿瘤(1.1 ± 0.3%ID/mL; p
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Combining poly-epitope MoonTags and labeled nanobodies for signal amplification in cell-specific PET imaging in vivo

Immunorecognition provides an excellent basis for targeted imaging techniques covering a wide range from basic research to diagnostics and from single cells to whole organisms. Fluorescence- or radioisotope-labeled antibodies, antibody fragments or nanobodies enable a direct signal readout upon binding and allow for versatile imaging from microscopy to whole-body imaging. However, as the signal intensity directly correlates with the number of labeled antibodies bound to their epitopes (1:1 binding), sensitivity for low-expressing epitopes can be limiting for visualization. For the first time, we developed poly-epitope tags with multiple copies (1 to 7) of a short peptide epitope, specifically the MoonTag, that are recognized by a labeled nanobody and aimed at signal amplification in microscopy and cell-specific PET imaging. In transiently transfected HeLa cells or stably transduced A4573 cells we characterized complex formation and in vitro signal amplification. Indeed, using fluorescently and radioactively labeled nanobodies we found an approximately linear signal amplification with increasing numbers of epitope copies in vitro. To test the poly-epitope approach in vivo, A4573 tumor cells were injected subcutaneously into the shoulder of NSG mice, with A4573 tumor cells expressing a poly-epitope of 7 MoonTags on one side and WT cells on the other side. Using a [68Ga]-labeled NODAGA-conjugated MoonTag nanobody, we performed PET/CT imaging at day 8–9 after tumor implantation. Specific binding of a [68Ga]-labeled NODAGA-conjugated MoonTag nanobody was observed in 7xMoonTag tumors (1.7 ± 0.5%ID/mL) by PET imaging, showing significantly higher radiotracer accumulation compared to the WT tumors (1.1 ± 0.3%ID/mL; p < 0.01). Ex vivo gamma counter measurements confirmed significantly higher uptake in 7xMoonTag tumors compared to WT tumors (p < 0.001). In addition, MoonTag nanobody binding was detected by autoradiography which was spatially matched with histological analysis of the tumor tissues. In conclusion, we expect nanobody-based poly-epitope tag strategies to be widely applicable for multimodal imaging techniques given the advantageous properties of nanobodies and their amenability to genetic and chemical engineering.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nuclear medicine and biology
Nuclear medicine and biology 医学-核医学
CiteScore
6.00
自引率
9.70%
发文量
479
审稿时长
51 days
期刊介绍: Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
期刊最新文献
225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates Evaluation of chelating agents based on pyridine-azacrown compounds H4PATA, PATAM, and H4PATPA for 68Ga and 177Lu In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles The potential of targeted radionuclide therapy to treat hypoxic tumor cells New prospects for 89Zr-immuno-PET in brain applications – Alpha-synucleinopathies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1